ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2062

Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US

Sandra Sze-jung Wu1, Allison Perry2, Nicole Zimmerman3, Helen Varker4, Rich Bizier4, Liisa Palmer4, Christine Dube5 and Gary Bryant6, 1AstraZeneca, Hockessin, DE, 2IBM Watson Health, New York, NY, 3IBM Watson Health, Chagrin Falls, OH, 4Merative, Cambridge, MA, 5AstraZeneca, Torrington, CT, 6AstraZeneca, New Castle, DE

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Decision analysis, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an SLE flare among patients remains a challenge for physicians.

To identify risk factors associated with SLE flares requiring an emergency room visit (ER) or inpatient (IP) admission, among Medicaid enrollees with prevalent SLE using an easy-to-implement predictive decision tree model.

Methods: Patients with SLE were selected from IBM MarketScan Multi-State Medicaid Database (2013-2019) based on ≥1 inpatient claim with a SLE diagnosis, or ≥2 non-diagnostic SLE outpatient claims. A prevalent cohort was created by randomly selecting an index date ≥12 months following first SLE claim. Also required: continuous medical and pharmacy benefits for 12 months pre-index (baseline) and post-index (Year 2) and valid steroid prescription claims. SLE flares were defined using published algorithm based on presence of SLE-related treatment and diagnoses.1 A classification and regression tree (CART) model was constructed to examine combinations of factors associated with developing SLE flares. Data were randomly split into training (75%) and validation (25%) datasets. At each node, the tree was split on the predictor and split value that minimized the Gini impurity. Predictors included demographic characteristics as well as baseline comorbid conditions, medication use, ER visits, and IP admissions. Splitting continued until maximum tree depth, and then pruned by penalizing the purity criterion. The optimal complexity parameter was selected using 10-fold cross validation repeated 10 times. The validation dataset was used to evaluate the tree’s predictive performance based on the area under the receiver operator curve (ROC) and the Brier score. The predicted probability (Pr) of having an ER/IP flare was computed for each patient in the validation dataset.

Results: Patients without a baseline ER visit had the lowest probability of a year-2 inpatient or ER flare (Pr(Flare)=0.185), while patients with a baseline ER visit, a baseline IP admission, and evidence of non-paralysis neurological disorders had the highest probability of an IP or ER flare in year 2 (Pr(Flare)=0.708). Presence of opioid prescriptions, chronic kidney disease or renal failure, and depression also increase the probability of a future inpatient or ER flare. The C-statistic for the selected covariates was 0.72. Based on the CART model, the leading patient characteristics related to any IP or ER flare in year 2 included opioids (variable importance = 1.00), other neurological disorders (0.96), any baseline ER visit (0.92), any inpatient admission (0.89), depression (0.64), and chronic kidney disease or renal failure (0.32).

Conclusion: The model effectively identified subgroups of Medicaid insured SLE patients with particularly high probabilities for an SLE flare. In addition, the model identified that resorting to opioids for pain management was the most important individual predictor of an SLE flare, and therefore an important marker of Medicaid patients in need of more effective SLE disease management.

1. Garris C, et al. J Med Econ. 2013;16(5):667-677.

Supporting image 1

Supporting image 2

Supporting image 3

The following characteristics were also included in the model, but had a variable importance of 0.000: Age ≥ 45, Age ≥ 65, Sex, Insurance Plan Type, Cancer, Chronic pulmonary disease, Coagulopathy, Congestive heart failure, Diabetes, Drug abuse, Liver disease, Peripheral vascular disorders, Anxiety, Atherosclerosis, Cerebrovascular disease, stroke, or TIA, Endocarditis, Myocardial infarction, Fibromyalgia, Fractures, Kidney Transplant, Osteoarthritis, Osteoporosis, Pleurisy/Pleural Effusion, Raynaud’s Disease, Thrombocytopenia, Antidepressants, Antihypertensives


Disclosures: S. Wu, AstraZeneca; A. Perry, None; N. Zimmerman, IBM Watson Health, GlaxoSmithKlein(GSK), AstraZeneca; H. Varker, None; R. Bizier, None; L. Palmer, None; C. Dube, AstraZeneca; G. Bryant, AstraZeneca, AstraZeneca.

To cite this abstract in AMA style:

Wu S, Perry A, Zimmerman N, Varker H, Bizier R, Palmer L, Dube C, Bryant G. Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/predicting-severe-flares-real-world-application-of-a-decision-tree-model-among-the-medicaid-insured-systemic-lupus-erythematosus-sle-population-in-the-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-severe-flares-real-world-application-of-a-decision-tree-model-among-the-medicaid-insured-systemic-lupus-erythematosus-sle-population-in-the-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology